BIOA Stock Analysis: Buy, Sell, or Hold?
BIOA - BioAge Labs, Inc. Common Stock
$9.48
-0.21 (-2.17%)
▼
5d:
-10.57%
30d:
-56.71%
90d:
-43.37%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When BIOA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BIOA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: BIOA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: BIOA is currently trading at $9.48, which is considered oversold relative to its 30-day fair value range of $9.76 to $21.49.
Technical Outlook: Technically, BIOA is showing sideways momentum. The price is currently testing key support at $9.48. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BIOA scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.62 (+275.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BIOA is showing sideways momentum. The price is currently testing key support at $9.48. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BIOA scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.62 (+275.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.76 -
$21.49
Company Quality Score
55/100
(HOLD)
Options IV Signal
19th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
95.8%
Protect Your Profits
Holding BIOA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 19th percentile)
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 275.8% below Wall St target ($35.62)
- CAUTION: Bottoming setup, but lagging the sector by 56% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-10.6%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$9.76 -
$21.49
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.87
(9.2%)
Support & Resistance Levels
Support Level
$9.48
Resistance Level
$11.89
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.02
Wall Street Target
$35.63
(+275.8%)
Revenue Growth (YoY)
1.6%
Share & Embed Analysis
Last updated: August 23, 2026 8:36 PM ET
Data refreshes hourly during market hours. Next update: 9:36 PM
Data refreshes hourly during market hours. Next update: 9:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIOA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced BIOA Option Strategies
Professional options setups generated by AI based on today's BIOA price and gamma walls.
